X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (430) 430
Patent (351) 351
Publication (12) 12
Conference Proceeding (8) 8
Book / eBook (5) 5
Book Review (1) 1
Compact Disc (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
electricity (154) 154
humans (123) 123
physics (115) 115
basic electric elements (104) 104
male (93) 93
index medicus (85) 85
performing operations (80) 80
transporting (80) 80
capacitors (79) 79
capacitors, rectifiers, detectors, switching devices orlight-sensitive devices, of the electrolytic type (79) 79
chemistry (77) 77
female (77) 77
metallurgy (77) 77
calculating (71) 71
computing (71) 71
counting (71) 71
middle aged (65) 65
electric digital data processing (64) 64
electric techniques not otherwise provided for (64) 64
aged (62) 62
casings or constructional details of electric apparatus (62) 62
manufacture of assemblages of electrical components (62) 62
printed circuits (62) 62
electric communication technique (46) 46
oncology (43) 43
electric solid state devices not otherwise provided for (42) 42
semiconductor devices (42) 42
adult (41) 41
cancer (35) 35
japan (33) 33
human necessities (31) 31
animals (29) 29
measuring (27) 27
organic chemistry (27) 27
testing (27) 27
heterocyclic compounds (24) 24
telephonic communication (24) 24
investigating or analysing materials by determining theirchemical or physical properties (23) 23
treatment outcome (23) 23
chemotherapy (22) 22
general tagging of cross-sectional technologies spanning over several sections of the ipc (22) 22
general tagging of new technological developments (22) 22
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (22) 22
compositions based thereon (21) 21
organic macromolecular compounds (21) 21
physical or chemical processes or apparatus in general (21) 21
surgery (21) 21
their preparation or chemical working-up (21) 21
analysis (20) 20
data processing systems or methods, specially adapted foradministrative, commercial, financial, managerial, supervisoryor forecasting purposes (20) 20
systems or methods specially adapted for administrative,commercial, financial, managerial, supervisory or forecastingpurposes, not otherwise provided for (20) 20
aged, 80 and over (19) 19
hygiene (19) 19
medical or veterinary science (19) 19
retrospective studies (19) 19
vehicles in general (19) 19
medicine & public health (18) 18
prognosis (18) 18
patients (17) 17
preparations for medical, dental, or toilet purposes (17) 17
research (17) 17
urology & nephrology (17) 17
care and treatment (16) 16
metastasis (16) 16
mice (16) 16
separation (16) 16
specific therapeutic activity of chemical compounds ormedicinal preparations (16) 16
working of plastics (16) 16
working of substances in a plastic state, in general (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
handling record carriers (15) 15
presentation of data (15) 15
recognition of data (15) 15
record carriers (15) 15
after-treatment not covered by subclasses c08b, c08c, c08f,c08g (14) 14
expression (14) 14
general processes of compounding (14) 14
survival rate (14) 14
working-up (14) 14
acyclic or carbocyclic compounds (13) 13
after-treatment of the shaped products, e.g. repairing (13) 13
breast cancer (13) 13
lining machines (13) 13
neoplasm staging (13) 13
printing (13) 13
prostate cancer (13) 13
shaping of material in a plastic state, not otherwise providedfor (13) 13
shaping or joining of plastics (13) 13
stamps (13) 13
tumors (13) 13
typewriters (13) 13
abridged index medicus (12) 12
adolescent (12) 12
cinematography (12) 12
compositions of macromolecular compounds (12) 12
correction of typographical errors (12) 12
diagnosis (12) 12
electrography (12) 12
holography (12) 12
i.e. mechanisms printing otherwise than from a forme (12) 12
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Gerstein Science - Stacks (2) 2
Art - Library use only (1) 1
Music - Circulation Desk (1) 1
Robarts - Stacks (1) 1
Royal Ontario Museum - Archives (1) 1
Royal Ontario Museum - Far Eastern (1) 1
Royal Ontario Museum - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (740) 740
Japanese (49) 49
German (42) 42
French (36) 36
Chinese (13) 13
Korean (8) 8
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue suppl_7
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, Issue suppl 7, pp. vii48.3 - vii48
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 06/2017, Volume 44, Issue 6, pp. 463 - 467
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 06/2017, Volume 44, Issue 6, p. 463
Soft tissue sarcomas are rare disease and the development of efficacious drug is urgently needed. The challenge is continuing, and recently 2 drugs,... 
Humans | Drug Design | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Sarcoma - drug therapy
Journal Article
Cancer Science, ISSN 1347-9032, 06/2016, Volume 107, Issue 6, pp. 755 - 763
This phase I study in Japanese patients evaluated the safety, pharmacokinetics, and preliminary efficacy of palbociclib, a highly selective and reversible oral... 
letrozole | Breast cancer | cyclin‐dependent kinase | Japanese | palbociclib | cyclin-dependent kinase | CELLS | ADVANCED BREAST-CANCER | ONCOLOGY | PROLIFERATION | PD 0332991 | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Neutrophils - cytology | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - therapeutic use | Pyridines - administration & dosage | Japan | Neoplasms - enzymology | Piperazines - therapeutic use | Piperazines - adverse effects | Neoplasms - drug therapy | Survival Analysis | Aged | Neoplasms - pathology | Medical research | Chemotherapy | Estrogen | Colorectal cancer | Clinical trials | Medicine, Experimental | Dosage and administration | Postmenopausal women | Cancer | Research funding | Menopause | Metastasis | Radiation therapy | Cancer therapies | Patients | Post-menopause | Esophagus | Epidermal growth factor | Womens health | Rectum | Cell cycle | Solid tumors | Pharmacokinetics | Neutropenia | Tumors | Original
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Cancer Science, ISSN 1347-9032, 10/2016, Volume 107, Issue 10, pp. 1465 - 1470
Human epidermal growth factor receptor 3 ( HER 3) expression in lung and breast cancers has a negative impact on survival. Patritumab, a human anti‐ HER 3 m A... 
trastuzumab | HER | metastasis | patritumab | Breast cancer | 3 protein | human | HER3 protein | SURVIVAL | ADVANCED SOLID TUMORS | U3-1287 | MONOCLONAL-ANTIBODY | PERTUZUMAB | DOCETAXEL | CELL LUNG-CANCER | ONCOLOGY | CARCINOMAS | EXPRESSION | HER3 | Antibodies, Neutralizing - administration & dosage | Gene Expression | Receptor, ErbB-2 - genetics | Trastuzumab - pharmacokinetics | Humans | Middle Aged | Kaplan-Meier Estimate | Antibodies, Monoclonal - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Biomarkers, Tumor | Breast Neoplasms - drug therapy | Neoplasm Metastasis | Breast Neoplasms - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Adult | Breast Neoplasms - mortality | Female | Aged | Neoplasm Staging | Antimitotic agents | Medical research | Epidermal growth factor | Analysis | Medicine, Experimental | Metastasis | Antineoplastic agents | Emerging markets | Family medical history | Cancer therapies | Metastases | Paclitaxel | Drug dosages | Neutropenia | Leukopenia | Research & development--R&D | Research funding | Diarrhea | Survival | ErbB-2 protein | Patients | Studies | Chemotherapy | Alopecia | Monoclonal antibodies | Biomarkers | Antitumor activity | Pharmacokinetics | Trastuzumab | Pharmaceuticals | Tumors | Original
Journal Article
Cancer Science, ISSN 1347-9032, 05/2016, Volume 107, Issue 5, pp. 659 - 665
TAS ‐102, a novel oral antitumor agent, consists of trifluridine and tipiracil hydrochloride (molar ratio, 1:0.5). We investigated the effects of food on... 
pharmacokinetics | Effect of food | 102 | tipiracil hydrochloride | trifluridine | TAS | TAS-102 | Tipiracil hydrochloride | Trifluridine | Pharmacokinetics | VIVO | 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE | ANTITUMOR-ACTIVITY | CANCER | TRIAL | ONCOLOGY | FLUORINATED PYRIMIDINES | DEOXYRIBONUCLEIC ACID | THYMIDINE PHOSPHORYLASE | Neoplasms - metabolism | Thymine - pharmacokinetics | Nausea - chemically induced | Area Under Curve | Humans | Middle Aged | Pyrrolidines - adverse effects | Biological Availability | Male | Antineoplastic Agents - therapeutic use | Trifluridine - pharmacokinetics | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Uracil - pharmacology | Antineoplastic Agents - adverse effects | Leukopenia - chemically induced | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Thymine - pharmacology | Neutropenia - chemically induced | Trifluridine - pharmacology | Fasting | Thymine - therapeutic use | Thymine - adverse effects | Pyrrolidines - pharmacokinetics | Food-Drug Interactions | Japan | Anemia - chemically induced | Uracil - therapeutic use | Neoplasms - drug therapy | Cross-Over Studies | Trifluridine - therapeutic use | Asian Continental Ancestry Group | Uracil - adverse effects | Trifluridine - adverse effects | Aged | Neoplasms - pathology | Uracil - pharmacokinetics | Drug Combinations | Uracil - analogs & derivatives | Drugs | Complications and side effects | Care and treatment | Safety and security measures | Analysis | Colorectal cancer | Prostate cancer | Tumors | Food | Lung cancer | Metastasis | Cancer therapies | Thymus | Consent | Safety | Meals | Drug dosages | Neutropenia | Leukopenia | Hematology | Research funding | Neutrophils | Nausea | Leukocytes (neutrophilic) | Bioavailability | Patients | Studies | Rectum | Breast | Clinical medicine | Solid tumors | Prostate | Pharmaceuticals | TAS‐102 | Original
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1512 - 1522
Antibody–drug conjugates have emerged as a powerful strategy in cancer therapy and combine the ability of monoclonal antibodies to specifically target tumour... 
HETEROGENEITY | EMTANSINE | THERAPY | ONCOLOGY | CANCER AMERICAN SOCIETY | CLINICAL-PRACTICE GUIDELINE | GENE AMPLIFICATION | JUNCTION CANCER | HER2 STATUS | OPEN-LABEL | PLUS PACLITAXEL | Breast Neoplasms - surgery | Prognosis | Receptor, ErbB-2 - genetics | Trastuzumab - pharmacokinetics | Humans | Middle Aged | Mastectomy - methods | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Patient Safety | Esophageal Neoplasms - mortality | Immunoconjugates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Receptor, ErbB-2 - drug effects | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Drug Administration Schedule | Japan | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - genetics | Esophageal Neoplasms - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Antimitotic agents | Care and treatment | Safety and security measures | Monoclonal antibodies | Antineoplastic agents | Biopharmaceutics | Tumors | Enzymes | Medical research | Analysis | Medicine, Experimental | Health aspects
Journal Article
Cancer Science, ISSN 1347-9032, 12/2014, Volume 105, Issue 12, pp. 1576 - 1583
Journal Article
Investigational New Drugs, ISSN 0167-6997, 06/2017, Volume 35, Issue 3, pp. 307 - 314
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
MEDICINA-LITHUANIA, ISSN 1010-660X, 03/2019, Volume 55, Issue 3, p. 77
Background and objectives: The purpose of this study was to compare the energy expenditures (EE) of a single sit-to-stand (STS) movements with slow and normal... 
OLDER-ADULTS | health promotion | MEDICINE, GENERAL & INTERNAL | COST | sedentary break | SEDENTARY BEHAVIOR | YOUNG | population strategy | weight control | RESISTANCE EXERCISE | stand up | energy cost | home-based exercise | non-exercise activity thermogenesis (NEAT)
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.